Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
TECX
Upturn stock ratingUpturn stock rating

Tectonic Therapeutic, Inc. (TECX)

Upturn stock ratingUpturn stock rating
$19.8
Last Close (24-hour delay)
Profit since last BUY-12.31%
upturn advisory
SELL
SELL since 1 day
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: TECX (3-star) is a SELL. SELL since 1 days. Profits (-12.31%). Updated daily EoD!

Upturn Star Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Number of Analysts

rating

6 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

Year Target Price $83.6

Year Target Price $83.6

Analyst’s Price TargetsFor last 52 week
$83.6Target price
Low$13.7
Current$19.8
high$61.07

Analysis of Past Performance

Type Stock
Historic Profit 140.04%
Avg. Invested days 52
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 369.72M USD
Price to earnings Ratio -
1Y Target Price 82.33
Price to earnings Ratio -
1Y Target Price 82.33
Volume (30-day avg) -
Beta -
52 Weeks Range 13.70 - 61.07
Updated Date 06/29/2025
52 Weeks Range 13.70 - 61.07
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.14

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -22.89%
Return on Equity (TTM) -41.6%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 66101678
Price to Sales(TTM) -
Enterprise Value 66101678
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 18672500
Shares Floating 8767116
Shares Outstanding 18672500
Shares Floating 8767116
Percent Insiders 38.29
Percent Institutions 59.52

Analyst Ratings

Rating 4.83
Target Price 83.6
Buy 1
Strong Buy 5
Buy 1
Strong Buy 5
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Tectonic Therapeutic, Inc.

stock logo

Company Overview

overview logo History and Background

Tectonic Therapeutic, Inc. is a biotechnology company focused on discovering and developing novel biologic therapies targeting G protein-coupled receptors (GPCRs). Founded to leverage insights into GPCR structure and function, the company aims to address unmet medical needs by creating targeted therapies.

business area logo Core Business Areas

  • GPCR-Targeted Biologics Discovery: Development of therapeutic antibodies and other biologics targeting GPCRs. Focus on novel approaches to modulate GPCR signaling.
  • Drug Development and Clinical Trials: Conducting preclinical research, clinical trials, and pursuing regulatory approvals for drug candidates. This includes lead optimization, formulation development, and manufacturing.
  • Technology Platform Development: Advancing their GEODeS platform for GPCR drug discovery. This includes improving computational modeling, protein engineering, and high-throughput screening capabilities.

leadership logo Leadership and Structure

The leadership team consists of experienced professionals in drug discovery, development, and business strategy. The organizational structure includes research, development, clinical, and administrative departments.

Top Products and Market Share

overview logo Key Offerings

  • TECT-001 (GPCR antibody): TECT-001 is Tectonic's lead program, focusing on a specific GPCR target in oncology. Currently in preclinical development. Market share is not yet applicable as it is not on the market. Competitors depend on the indication and target of TECT-001. Large Pharma companies like Roche (RHHBY), Novartis (NVS), and smaller biotech companies working on GPCR-targeted therapies are potential competitors.

Market Dynamics

industry overview logo Industry Overview

The biotechnology industry is experiencing rapid growth with advances in drug discovery technologies and increasing investment in novel therapeutics. GPCR-targeted therapies represent a significant market opportunity due to their involvement in various diseases.

Positioning

Tectonic Therapeutic, Inc. is positioned as an innovator in GPCR-targeted biologics, leveraging its GEODeS platform to discover and develop differentiated therapies. Its competitive advantages include a focus on complex GPCR targets and innovative drug discovery approaches.

Total Addressable Market (TAM)

The TAM for GPCR-targeted therapies is substantial, estimated to be in the tens of billions of dollars, depending on the specific indication and market penetration. Tectonic is positioned to capture a portion of this TAM by developing novel biologics for high-value targets.

Upturn SWOT Analysis

Strengths

  • Proprietary GEODeS platform for GPCR drug discovery
  • Experienced leadership team
  • Focus on difficult-to-drug GPCR targets
  • Potential for first-in-class biologics

Weaknesses

  • Early-stage pipeline with significant development risk
  • Reliance on successful clinical trial outcomes
  • Dependence on raising capital to fund operations
  • Limited commercial infrastructure

Opportunities

  • Partnering with larger pharmaceutical companies
  • Expanding the GEODeS platform to new GPCR targets
  • Securing regulatory approvals for lead candidates
  • Addressing unmet medical needs in various diseases

Threats

  • Competition from established pharmaceutical companies
  • Clinical trial failures
  • Regulatory hurdles
  • Changes in the competitive landscape

Competitors and Market Share

competitor logo Key Competitors

  • LLY
  • NVS
  • MRK
  • VRTX

Competitive Landscape

Tectonic Therapeutic, Inc. faces competition from established pharmaceutical companies with existing GPCR-targeted therapies and other biotechnology companies developing novel approaches. Tectonic aims to differentiate itself through its GEODeS platform and focus on challenging GPCR targets.

Growth Trajectory and Initiatives

Historical Growth: Growth is measured by advancement of drug candidates through preclinical and clinical development, securing partnerships, and raising capital.

Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization of products. Analyst estimates are not available without public trading history.

Recent Initiatives: Recent initiatives include advancing lead programs towards clinical trials, expanding the GEODeS platform, and exploring potential partnerships.

Summary

Tectonic Therapeutic, Inc. is a preclinical stage biotechnology company focused on GPCR-targeted therapies, offering innovative approaches with its GEODeS platform. Its strengths lie in its technology and experienced team, but success hinges on clinical trial outcomes and securing funding. Threats include competition and regulatory hurdles, with opportunities arising from partnerships and platform expansion. Overall the company exhibits average fundamentals and has lots of oppourtunity, but needs to be aware of other public companies that can compete with them.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings (if available)
  • Industry reports
  • Press releases
  • Analyst reports

Disclaimers:

This analysis is based on publicly available information and does not constitute financial advice. Market share data is estimated and may not be precise. The AI-based rating is based on a limited dataset and should be used as a reference point.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Tectonic Therapeutic, Inc.

Exchange NASDAQ
Headquaters Watertown, MA, United States
IPO Launch date 2018-06-21
President, CEO, Secretary & Director Dr. Alise S. Reicin M.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 51
Full time employees 51

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.